Role of the ADAM33 rs2280091 Variant in Modulating Lung Function in Cystic Fibrosis

Area of Science:

• Genetics
• Pulmonology
• Biochemistry

Background:

• Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene variants, with severity influenced by modifier genes like ADAM33.
• The ADAM33 rs2280091 variant's role in CF lung function variability is not fully understood.

Purpose of the Study:

• To investigate the association between the ADAM33 rs2280091 variant and lung function in Brazilian CF patients.
• To determine if this genetic variant influences disease severity or progression.

Main Methods:

• Cross-sectional study of 55 CF patients.
• Genotyping of the ADAM33 rs2280091 variant using PCR-RFLP.
• Pulmonary function tests (spirometry) before and after bronchodilator administration.

Main Results:

• The GG genotype of ADAM33 rs2280091 was significantly enriched in CF patients (18.2%) compared to controls (0.02%), with an OR of 12.06.
• Carriers of the GG genotype or G allele showed improved peripheral airway function (FEF25%, FEF50%, FEF25-75%, MEF) and bronchodilator responsiveness.
• The G allele was more frequent in CF patients, but this might reflect a survivor effect.

Conclusions:

• The ADAM33 rs2280091 variant, particularly the G allele, is associated with altered peripheral airway function and bronchodilator response in CF patients.
• Findings suggest a potential modulatory role of ADAM33 in CF lung function.
• The observed association may be influenced by a survivor bias, where carriers of the G allele are more likely to be recruited for studies.